CD4 and influenza: Intranasal or intramuscular prime-boost administration of VLPs containing M2e tandem repeats of influenza from different host species conferred heterosubtypic immunity with effective IgG2a (Th1 cells response), CD4+ and CD8+ T-cell responses, and superiority over commercial influenza SVVs and HA-based VLPs (278–281).